Clinical Pharmacokinetics

, Volume 30, Issue 4, pp 314–327 | Cite as

Pharmacokinetic Individualisation of Zidovudine Therapy

Current State of Pharmacokinetic-Pharmacodynamic Relationships
  • Richard M. W. Hoetelmans
  • David M. Burger
  • Pieter L. Meenhorst
  • Jos H. Beijnen
Review Article Pharmacokinetic-Pharmacodynamic Relationships


Zidovudine is the cornerstone of current antiretroviral treatment of human immunodeficiency virus (HIV) infection. Its use, however, frequently leads to adverse reactions, including myelosuppression. Zidovudine pharmacokinetic s show large interindividual variation with indications of pharmacokinetic-pharmacodynamic relationships, but a clear therapeutic window has not yet been defined. Individualisation of zidovudine therapy with monitoring of drug concentrations might be desirable. This review considers (intracellular) monitoring of zidovudine and anabolites for individualisation of zidovudine therapy and the achievements in describing pharmacokinetic-pharmacodynamic relationships so far.


Human Immunodeficiency Virus Zidovudine Antimicrob Agent Zidovudine Therapy Large Interindividual Variation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Horwitz JP, Chua J, Noel M. Nucleosides. V: The monomesylates of 1-(2′-deoxy-beta-D-lyxofuranosyl) thymidine. J Org Chem 1964; 29: 2076–8CrossRefGoogle Scholar
  2. 2.
    Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096–100PubMedCrossRefGoogle Scholar
  3. 3.
    Hirsch MS, D’Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328: 1686–95PubMedCrossRefGoogle Scholar
  4. 4.
    Portegies P, De Gans J, Lange JMA, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989; 299: 819–21PubMedCrossRefGoogle Scholar
  5. 5.
    Schmitt FA, Bigley JW, McKinnis R, et al. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1988; 319: 1573–8PubMedCrossRefGoogle Scholar
  6. 6.
    Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989; 37: 408–50PubMedCrossRefGoogle Scholar
  7. 7.
    Kong X-B, Zhu Q-Y, Vidal PM, et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetic s of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992; 36: 808–18PubMedCrossRefGoogle Scholar
  8. 8.
    Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333–7PubMedCrossRefGoogle Scholar
  9. 9.
    Oates JA, Wood AJJ. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726–38CrossRefGoogle Scholar
  10. 10.
    Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989; 264: 6127–33PubMedGoogle Scholar
  11. 11.
    Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo anti-retrovirus activity and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988; 37: 897–903PubMedCrossRefGoogle Scholar
  12. 12.
    Cheng YC, Dutschman GE, Bastow KF, et al. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987; 262: 2187–9PubMedGoogle Scholar
  13. 13.
    St. Clair MH, Richards CA, Spector T, et al. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987; 31: 1972–7CrossRefGoogle Scholar
  14. 14.
    Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986; I(8481): 575–80CrossRefGoogle Scholar
  15. 15.
    Huang P, Farquhar D, Plunkett W. Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J Biol Chem 1990; 265: 11914–8PubMedGoogle Scholar
  16. 16.
    Mitsuya H, Jarrett RF, Matsukura M, et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 1987; 84: 2033–7PubMedCrossRefGoogle Scholar
  17. 17.
    Toji L, Cohen SS. The enzymatic termination of polydeoxynucleotides by 2′,3′-dideoxyadenosine triphosphate. Proc Natl Acad Sci USA 1969; 63: 871–7PubMedCrossRefGoogle Scholar
  18. 18.
    Sanger F, Nicklen S, Coulson AR. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463–7PubMedCrossRefGoogle Scholar
  19. 19.
    Tan CK, Civil R, Mian AM, et al. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate. Biochemistry 1991; 30: 4831–5PubMedCrossRefGoogle Scholar
  20. 20.
    Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990; 249: 1533–44PubMedCrossRefGoogle Scholar
  21. 21.
    Waqar MA, Evans MJ, Manly KF. Effects of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984; 121: 402–8PubMedCrossRefGoogle Scholar
  22. 22.
    Harrington JA, Reardon JE, Spector T. 3′-Azido-3′-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother 1993; 37: 918–20PubMedCrossRefGoogle Scholar
  23. 23.
    Sommadossi J-P, Carlisle R, Zhou Z. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989; 36: 9–14PubMedGoogle Scholar
  24. 24.
    Tosi P, Calabresi P, Goulette FA, et al. Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 1992; 52: 4069–73PubMedGoogle Scholar
  25. 25.
    Vazquez-Padua MA, Starnes MC, Cheng Y-C. Incorporation of 3′-azido-3′- deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 1990; 2: 55–62PubMedGoogle Scholar
  26. 26.
    Toyoshima T, Kimura S, Muramatsu S, et al. A sensitive non-isotopic method for the determination of intracellular azidothymidine 5′-mono-, 5′-di-, and 5′-triphosphate. Anal Biochem 1991; 196: 302–7PubMedCrossRefGoogle Scholar
  27. 27.
    Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1–5PubMedCrossRefGoogle Scholar
  28. 28.
    Cretton EM, Xie M-Y, Bevan RJ, et al. Catabolism of 3′-azido- 3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1991; 42: 1475–80Google Scholar
  29. 29.
    Avramis VI, Markson W, Jackson RL, et al. Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM). AIDS 1989; 3: 417–22PubMedCrossRefGoogle Scholar
  30. 30.
    Frick LW, Nelson DJ, St Clair MH, et al. Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun 1988; 154: 124–9PubMedCrossRefGoogle Scholar
  31. 31.
    Wilde MI, Langtry HD. Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46: 515–78PubMedCrossRefGoogle Scholar
  32. 32.
    Morse GD, Shelton MJ, O’Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993; 24: 101–23PubMedCrossRefGoogle Scholar
  33. 33.
    Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine: an overview of current data. Clin Pharmacokinet 1989; 17: 1–9PubMedCrossRefGoogle Scholar
  34. 34.
    Burger DM, Meenhorst PL, Beijnen JH. Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents. Pharm World Sci 1995; 17: 25–30PubMedCrossRefGoogle Scholar
  35. 35.
    Acosta EP, Page LM, Fletcher VF. Clinical pharamacokinetics of zidovudine: an update. Clin Pharmacokinet 1996 Apr; 30(4): 251–262PubMedCrossRefGoogle Scholar
  36. 36.
    Burger DM, Meenhorst PL, ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683–9PubMedCrossRefGoogle Scholar
  37. 37.
    Blum RM, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85 Suppl. 2A: 189–94PubMedGoogle Scholar
  38. 38.
    Cload PA. A review of the pharmacokinetics of zidovudine in man. J Infect 1989; 18 Suppl. 1: 15–21PubMedCrossRefGoogle Scholar
  39. 39.
    Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407–12PubMedCrossRefGoogle Scholar
  40. 40.
    Macnab KA, Gill MJ, Sutherland LR, et al. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993; 31: 421–8PubMedCrossRefGoogle Scholar
  41. 41.
    Zorza G, Beaugerie L, Taburet A-M, et al. Absorption of zidovudine in patients with diarrhoea. Eur J Clin Pharmacol 1993; 44: 501–3PubMedCrossRefGoogle Scholar
  42. 42.
    Drew RH, Weiler S, Gallis HA, et al. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33: 1801–3PubMedCrossRefGoogle Scholar
  43. 43.
    Unadkat JD, Collier AC, Crosby SS, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990; 4: 229–32PubMedCrossRefGoogle Scholar
  44. 44.
    Lotterer E, Ruhnke M, Trautmann M, et al. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305–8PubMedCrossRefGoogle Scholar
  45. 45.
    Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992; 33: 657–60PubMedCrossRefGoogle Scholar
  46. 46.
    Ruhnke M, Bauer FE, Seifert M, et al. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2153–8PubMedCrossRefGoogle Scholar
  47. 47.
    Shelton MJ, Portmore A, Blum R, et al. Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy 1994; 14: 671–7PubMedGoogle Scholar
  48. 48.
    Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990; 48: 161–7PubMedCrossRefGoogle Scholar
  49. 49.
    Rolinski B, Wintergerst U, Matuschke A, et al. Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1991; 5: 885–8PubMedCrossRefGoogle Scholar
  50. 50.
    Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581–7PubMedCrossRefGoogle Scholar
  51. 51.
    Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190–2PubMedCrossRefGoogle Scholar
  52. 52.
    Kuster H, Vogt M, Joos B, et al. A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991; 164: 773–6PubMedCrossRefGoogle Scholar
  53. 53.
    Slusher JT, Kuwahara SK, Hamzeh FM, et al. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatographyradioimmunoassay procedure. Antimicrob Agents Chemother 1992; 36: 2473–7PubMedCrossRefGoogle Scholar
  54. 54.
    Avramis VI, Kwock R, Solorzano MM, et al. Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6- 1/AZT-100) and in pediatric patients with HIV-1 infection. J Acquir Immune Defic Syndr 1993; 6: 1287–96PubMedGoogle Scholar
  55. 55.
    Stretcher BN, Pesce AJ, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994; 8: 763–9PubMedCrossRefGoogle Scholar
  56. 56.
    Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1541–7PubMedCrossRefGoogle Scholar
  57. 57.
    Robbins BL, Rodman J, McDonald C, et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994; 38: 115–21PubMedCrossRefGoogle Scholar
  58. 58.
    Shelton MJ, Morse GD, Portmore A, et al. Zidovudine recovered from peripheral blood mononuclear cells of HIV-infected patients [abstract P80]. International Congress on Drug Therapy in HIV Infection: 1992 Nov 9–12; Glasgow, Scotland. AIDS 1992 Nov; 6 (1 Suppl.): S35CrossRefGoogle Scholar
  59. 59.
    Stretcher BN, Pesce AJ, Hurtubise PE, et al. Pharmacokinetics of zidovudine phosphorylation in patients with the human immunodeficiency virus. Ther Drug Monk 1992; 14: 281–5CrossRefGoogle Scholar
  60. 60.
    Törnevik Y, Jacobsson B, Britton S, et al. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1991; 7: 751–9PubMedCrossRefGoogle Scholar
  61. 61.
    Fischl MA, Parker CB, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1009–14PubMedCrossRefGoogle Scholar
  62. 62.
    Sette P, Narciso P, Tozzi V, et al. Low-dose zidovudine for AIDS. Lancet 1989; I(8647): 1136–7CrossRefGoogle Scholar
  63. 63.
    Collier AC, Bozzette S, Coombs RW, et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990; 323: 1015–21PubMedCrossRefGoogle Scholar
  64. 64.
    Dournon E, Matheron S, Rozenbaum W, et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988; II(8623): 1297–302CrossRefGoogle Scholar
  65. 65.
    Hoggard PG, Veal GJ, Wild MJ, et al. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39: 1376–8PubMedCrossRefGoogle Scholar
  66. 66.
    Peter K, Gambertoglio J. Effect of long-term zidovudine (ZDV) administration on intracellular ZDV phosphorylation in HIV positive patients [abstract PII-56]. 69th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics: 1995 Mar 15–17; San Diego (CA). Clin Pharmacol Ther 1995; 54: 178Google Scholar
  67. 67.
    Stretcher BN. State-of-the-art of zidovudine monitoring. J Clin Lab Anal 1991; 5: 60–8PubMedCrossRefGoogle Scholar
  68. 68.
    Stretcher BN, Pesce AJ. Intracellular monitoring of nucleoside analogues: a new frontier. Ann Clin Lab Sci 1991; 21: 340–2PubMedGoogle Scholar
  69. 69.
    Stretcher BN, Pesce AJ, Murray JA, et al. Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations. Ther Drug Monit 1991; 13: 325–31PubMedCrossRefGoogle Scholar
  70. 70.
    Stretcher BN, Pesce AJ, Wermeling JR, et al. In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes. Ther Drug Monit 1990; 12: 481–9PubMedCrossRefGoogle Scholar
  71. 71.
    Mentré F, Escolano S, Diquet B, et al. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45: 397–407PubMedCrossRefGoogle Scholar
  72. 72.
    Bareggi SR, Cinque P, Mazzei M, et al. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. J Clin Pharmacol 1994; 34: 782–6PubMedGoogle Scholar
  73. 73.
    Taburet A-M, Naveau S, Zorza G, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther 1990; 47: 731–9PubMedCrossRefGoogle Scholar
  74. 74.
    Fletcher CV, Rhame FS, Beatty CC, et al. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992; 12: 429–34PubMedGoogle Scholar
  75. 75.
    Child S, Montaner J, Tsoukas C, et al. Canadian multicenter azidothymidine trial: AZT pharmacokinetics. J Acquir Immune Defic Syndr 1991; 4: 865–70PubMedGoogle Scholar
  76. 76.
    Singlas E, Pioger J-C, Taburet A-M, et al. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis. Clin Pharmacol Ther 1989; 46: 190–7PubMedCrossRefGoogle Scholar
  77. 77.
    Burger DM, Meenhorst PL, Mulder JW, et al. Pharmacokinetics of zidovudine and metabolites in a patient with HIV-associated nephropathy and severe renal impairment. Drug Invest 1994; 7: 282–7CrossRefGoogle Scholar
  78. 78.
    Burger DM, Meenhorst PL, Koks CW, et al. Drug interactions with zidovudine. AIDS 1993; 7: 445–60PubMedCrossRefGoogle Scholar
  79. 79.
    Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279–85PubMedGoogle Scholar
  80. 80.
    Chiang H, Shelton M, Hewitt R, et al. Relationship between surrogate marker response (SMR) and zidovudine population pharmacokinetics [abstract no. 319, session 32]. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 1993 Oct 17–20; New Orleans (LA).Google Scholar
  81. 81.
    Collier AC, Tartaglione T, Corey L. A reduced dose of zidovudine in patients with AIDS. N Engl J Med 1991; 324: 996CrossRefGoogle Scholar
  82. 82.
    Drusano GL, Balis FM, Gitterman SR, et al. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994; 38: 1726–31PubMedCrossRefGoogle Scholar
  83. 83.
    Gøtsche PC, Melander H, Norrby SR, et al. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. (Nordic Medical Research Councils’ HIV Therapy Group.) BMJ 1992; 304: 13–7CrossRefGoogle Scholar
  84. 84.
    Sale M, Sheiner LB, Volberding P, et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993; 54: 556–66PubMedCrossRefGoogle Scholar
  85. 85.
    Tartaglione TA, Collier AC, Coombs RW, et al. Acquired immunodeficiency syndrome: cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991; 48: 695–9PubMedCrossRefGoogle Scholar
  86. 86.
    Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9PubMedCrossRefGoogle Scholar
  87. 87.
    Barry M, Howe JL, Back DJ, et al. Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol 1994; 37: 7–12PubMedCrossRefGoogle Scholar
  88. 88.
    Baxter R, Drew WL, Enos L. Pharmacokinetics and toxicity of zidovudine [abstract no. 18]. 6th AIDS Clinical Trials Group Meeting: 1989 Jul; Bethesda (MD).Google Scholar
  89. 89.
    Gelmon K, Montaner JSG, Fanning M, et al. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS 1989; 3: 555–61PubMedCrossRefGoogle Scholar
  90. 90.
    Grau JM, Masanés F, Pedrol E, et al. Human immunodeficiency virus type 1 infection and myopathy: clinical relevance of zidovudine therapy. Ann Neurol 1993; 34: 206–11PubMedCrossRefGoogle Scholar
  91. 91.
    Koch MA, Volberding PA, Lagakos SW, et al. Toxic effects of zidovudine in asymptomatic human immunodeficiency virus-infected individuals with CD4+ cell counts of 0.50×109/L or less. Arch Intern Med 1992; 152: 2286–92PubMedCrossRefGoogle Scholar
  92. 92.
    Scherpbier HJ, Prakken ABJ, De Graeff-Meeder ER, et al. Treatment of 12 HIV-infected children with zidovudine [in Dutch]. Ned Tijdschr Geneeskd 1993; 137: 1610–3PubMedGoogle Scholar
  93. 93.
    Vocks-Hauck M, Wintergerst U, Rolinski B, et al. Side effects of zidovudine in correlation to plasma levels in children [abstract P86]. International Congress on Drug Therapy in HIV Infection: 1992 Nov 9–12; Glasgow, Scotland. AIDS 1992; 6 (1 Suppl.): S37Google Scholar
  94. 94.
    Tartaglione TA, Collier AC, Opheim K, et al. Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrob Agents Chemother 1991; 35: 2225–31PubMedCrossRefGoogle Scholar
  95. 95.
    Meng T-C, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann Intern Med 1992; 116: 13–20PubMedGoogle Scholar
  96. 96.
    Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989; 321: 1621–5PubMedCrossRefGoogle Scholar
  97. 97.
    Coombs RW, Collier AC, Allain J-P, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989; 321: 1626–31PubMedCrossRefGoogle Scholar
  98. 98.
    Piatak Jr M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749–54PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Richard M. W. Hoetelmans
    • 1
  • David M. Burger
    • 2
  • Pieter L. Meenhorst
    • 3
  • Jos H. Beijnen
    • 1
  1. 1.Department of PharmacySlotervaart HospitalAmsterdamThe Netherlands
  2. 2.Department of Clinical PharmacyUniversity Hospital NijmegenNijmegenThe Netherlands
  3. 3.Department of Internal MedicineSlotervaart HospitalAmsterdamThe Netherlands

Personalised recommendations